Abstract:The COVID-19 pandemic-led worldwide healthcare crisis necessitates prompt societal, ecological, and medical efforts to stop or reduce the rising number of fatalities. Numerous mRNA based vaccines and vaccines for viral vectors have been licensed for use in emergencies which showed 90% to 95% efficacy in preventing SARS-CoV-2 infection. However, safety issues, vaccine reluctance, and skepticism remain major concerns for making mass vaccination a successful approach to treat COVID-19. Hence, alternative therapeutics is needed for eradicating the global burden of COVID-19 from developed and low-resource countries. Repurposing current medications and drug candidates could be a more viable option for treating SARS-CoV-2 as these therapies have previously passed a number of significant checkpoints for drug development and patient care. Besides vaccines, this review focused on the potential usage of alternative therapeutic agents including antiviral, antiparasitic, and antibacterial drugs, protease inhibitors, neuraminidase inhibitors, and monoclonal antibodies that are currently undergoing preclinical and clinical investigations to assess their effectiveness and safety in the treatment of COVID-19. Among the repurposed drugs, remdesivir is considered as the most promising agent, while favipiravir, molnupiravir, paxlovid, and lopinavir/ritonavir exhibited improved therapeutic effects in terms of elimination of viruses. However, the outcomes of treatment with oseltamivir, umifenovir, disulfiram, teicoplanin, and ivermectin were not significant. It is noteworthy that combining multiple drugs as therapy showcases impressive effectiveness in managing individuals with COVID-19. Tocilizumab is presently employed for the treatment of patients who exhibit COVID-19-related pneumonia. Numerous antiviral drugs such as galidesivir, griffithsin, and thapsigargin are under clinical trials which could be promising for treating COVID-19 individuals with severe symptoms. Supportive treatment for patients of COVID-19 may involve the use of corticosteroids, convalescent plasma, stem cells, pooled antibodies, vitamins, and natural substances. This study provides an updated progress in SARS-CoV-2 medications and a crucial guide for inventing novel interventions against COVID-19.

Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities

Potential therapeutic options for COVID-19: an update on current evidence

An Update on Current Therapeutic Drugs Treating COVID-19

An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics

Update: Drug Treatment Options for Coronavirus Disease 2019 (COVID-19).

Current treatment strategies for COVID‐19 (Review)

Progress in SARS-CoV-2, Diagnostic and Clinical Treatment of COVID-19

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update

Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Plant‐derived compounds as potential leads for new drug development targeting COVID‐19

Therapeutic strategies for COVID-19: progress and lessons learned

Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies

Updated Approaches against SARS-CoV-2

Overview of Therapeutic Drug Research for COVID-19 in China

An update review of emerging small-molecule therapeutic options for COVID-19

Current status of potential therapeutic candidates for the COVID-19 crisis

Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants

A review of natural products, their effects on SARS-CoV-2 and their utility as lead compounds in the discovery of drugs for the treatment of COVID-19

Current state-of-the-art and potential future therapeutic drugs against COVID-19

Insights into Biological Therapeutic Strategies for COVID-19